golfyeti and KK2 - The answer is yes they could license this out per indication however it becomes very difficult to deal with so likely won't happen. That strategy may have the effect of to much competition between pharma's as crazy as that sounds. Someone with CKD get it for one price and someone with diabetes get it for another price and fabrys yet another price. It could happen but not likely.

We should know a lot more within a few short months.

tada